Literature DB >> 17406569

Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64.

Thaddeus J Wadas1, Carolyn J Anderson.   

Abstract

The number of radiopharmaceuticals containing copper radionuclides for diagnostic imaging and targeted radiotherapy has grown considerably over the past few decades. This expansion has created the need for protocols allowing for the efficient chelation of 64Cu to peptide-chelator conjugates. Step 1A of this protocol describes a (64)Cu-radiolabeling procedure for 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA)-conjugated peptides. This reaction is facile and requires the incubation of 64CuCl2 in 0.1 M ammonium acetate buffer with the TETA-peptide for 30 min at room temperature (20-23 degrees C). Step 1B of this protocol describes the radiolabeling procedure for 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A)-conjugated peptides. The CB-TE2A-peptide can be labeled with 64Cu in 0.1 M ammonium acetate buffer in 2 h at 95 degrees C. In both cases, the conjugates can be radiolabeled with 64Cu at greater than 95% purity and with specific activities of 37-111 MBq microg(-1) (1-3 mCi microg(-1)). Both protocols are straightforward and can be completed within 3 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406569     DOI: 10.1038/nprot.2006.431

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  37 in total

1.  Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.

Authors:  Yunjun Guo; Riccardo Ferdani; Carolyn J Anderson
Journal:  Bioconjug Chem       Date:  2012-06-18       Impact factor: 4.774

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.

Authors:  Zhengxin Cai; Barbara T Y Li; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Dalton Trans       Date:  2015-03-07       Impact factor: 4.390

Review 4.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

5.  Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

Authors:  William M Rockey; Ling Huang; Kyle C Kloepping; Nicholas J Baumhover; Paloma H Giangrande; Michael K Schultz
Journal:  Bioorg Med Chem       Date:  2011-05-14       Impact factor: 3.641

Review 6.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 7.  A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.

Authors:  Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara
Journal:  Ann Biomed Eng       Date:  2013-09-10       Impact factor: 3.934

8.  Microfluidic radiolabeling of biomolecules with PET radiometals.

Authors:  Dexing Zeng; Amit V Desai; David Ranganathan; Tobias D Wheeler; Paul J A Kenis; David E Reichert
Journal:  Nucl Med Biol       Date:  2012-10-15       Impact factor: 2.408

9.  New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.

Authors:  Yongkang Gai; Lingyi Sun; Wenqi Hui; Qin Ouyang; Carolyn J Anderson; Guangya Xiang; Xiang Ma; Dexing Zeng
Journal:  Inorg Chem       Date:  2016-06-27       Impact factor: 5.165

10.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Authors:  Carolyn J Anderson; Riccardo Ferdani
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.